Full scope of effect of facial lipoatrophy: A framework of disease understanding

被引:60
作者
Ascher, Benjamin
Coleman, Sydney
Alster, Tina
Bauer, Ute
Burgess, Cheryl
Butterwick, Kimberly
Donofrio, Lisa
Engelhard, Peter
Goldman, Mitchel P.
Katz, Philippe
Vleggaar, Danny
机构
[1] Paris Acad, Clin Iena, F-75116 Paris, France
[2] Tribeca Plast Surg, New York, NY USA
[3] Washington Inst Dermatol Laser Surg, Washington, DC USA
[4] Azienda Osped Padova, Chirurg Plast Pediat, Padua, Italy
[5] La Jolla Spa MD, La Jolla, CA USA
[6] Ctr Dermatol & Dermatol Surg, Washington, DC USA
[7] Savin Ctr, New Haven, CT USA
[8] Apex S Beach Laser & Med Skin Care, Miami Beach, FL USA
[9] Amer Hosp Paris, Inst Explorat Fonctionnelles Glandes Salivaires, Paris, France
[10] Nouvelle Clin Vert Pre, Geneva, Switzerland
关键词
D O I
10.1111/j.1524-4725.2006.32230.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND Facial lipoatrophy has been observed to occur in a variety of patient populations, with inherited or acquired disease, or even in aging patients as a natural progression of tissue change over time. There is currently no framework from which physicians of all medical specialties can communally discuss the manifestations, diagnoses, and management of facial lipoatrophy. OBJECTIVE The aim of this assembly was to derive a definition of facial lipoatrophy capable of being applied to all patient populations and develop an accompanying grading system. RESULTS The final consensus of the Facial Lipoatrophy Panel encompasses both aging and disease states: "Loss of facial fat due to aging, trauma or disease, manifested by flattening or indentation of normally convex contours." The proposed grading scale includes five gradations (Grades 1-5; 5 being the most severe), and the face is assessed according to three criteria: contour, bony prominence, and visibility of musculature. CONCLUSION Categorizing the presentation of facial lipoatrophy is subjective and qualitative, and will need to be validated with objective measures. Furthermore, during the assembly, several topics were exposed that warrant further research, including the physiology of volume loss, age and lipoatrophy, and human immunodeficiency virus and lipoatrophy.
引用
收藏
页码:1058 / 1069
页数:12
相关论文
共 34 条
[1]  
AMARD P, 2000, ANTIVIR THER S5, V5, P79
[2]   Relationship between HAART adherence and adipose tissue alterations [J].
Ammassari, A ;
Antinori, A ;
Cozzi-Lepri, A ;
Trotta, MP ;
Nasti, G ;
Ridolfo, AL ;
Mazzotta, F ;
Wu, AW ;
D'Arminio Monforte, A ;
Galli, M .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 :S140-S144
[3]  
Boyde A, 1998, Gerodontology, V15, P25, DOI 10.1111/j.1741-2358.1998.00025.x
[4]   An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score [J].
Carr, A ;
Law, M .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (05) :571-576
[5]   A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].
Carr, A ;
Miller, J ;
Law, M ;
Cooper, DA .
AIDS, 2000, 14 (03) :F25-F32
[6]   Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430
[7]  
Collins E, 2000, AIDS Read, V10, P546
[8]   Fat distribution: a morphologic study of the aging face [J].
Donofrio, LM .
DERMATOLOGIC SURGERY, 2000, 26 (12) :1107-1112
[9]   The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men [J].
Dukers, NHTM ;
Stolte, IG ;
Albrecht, N ;
Coutinho, RA ;
de Wit, JBF .
AIDS, 2001, 15 (06) :812-813
[10]   Failure to maintain long-term adherence to highly active antiretroviral therapy:: the role of lipodystrophy [J].
Duran, S ;
Savès, M ;
Spire, B ;
Cailleton, V ;
Sobel, A ;
Carrieri, P ;
Salmon, D ;
Moatti, JP ;
Leport, C .
AIDS, 2001, 15 (18) :2441-2444